Loading…

Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development

Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed i...

Full description

Saved in:
Bibliographic Details
Published in:Translational oncology 2018-08, Vol.11 (4), p.1012-1022
Main Authors: Gu, Yan, Chow, Mathilda Jing, Kapoor, Anil, Mei, Wenjuan, Jiang, Yanzhi, Yan, Judy, De Melo, Jason, Seliman, Maryam, Yang, Huixiang, Cutz, Jean-Claude, Bonert, Michael, Major, Pierre, Tang, Damu
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123
cites cdi_FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123
container_end_page 1022
container_issue 4
container_start_page 1012
container_title Translational oncology
container_volume 11
creator Gu, Yan
Chow, Mathilda Jing
Kapoor, Anil
Mei, Wenjuan
Jiang, Yanzhi
Yan, Judy
De Melo, Jason
Seliman, Maryam
Yang, Huixiang
Cutz, Jean-Claude
Bonert, Michael
Major, Pierre
Tang, Damu
description Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed in PC and its impact on PC remain unclear. We report here the biphasic changes of BChE expression in PC. In vitro, BChE expression was decreased in more tumorigenic PC stem-like cells (PCSLCs), DU145, and PC3 cells compared to less tumorigenic non-stem PCs and LNCaP cells. On the other hand, BChE was expressed at a higher level in LNCaP cells than immortalized but non-tumorigenic prostate epithelial BPH-1 cells. In vivo, BChE expression was up-regulated in DU145 xenografts compared to LNCaP xenografts; DU145 cell-derived lung metastases displayed comparable levels of BChE as subcutaneous tumors. Furthermore, LNCaP xenografts produced in castrated mice exhibited a significant increase of BChE expression compared to xenografts generated in intact mice. In patients, BChE expression was down-regulated in PCs (n = 340) compared to prostate tissues (n = 86). In two independent PC populations MSKCC (n = 130) and TCGA Provisional (n = 490), BChE mRNA levels were reduced from World Health Organization grade group 1 (WHOGG 1) PCs to WHOGG 3 PCs, followed by a significant increase in WHOGG 5 PCs. The up-regulation was associated with a reduction in disease-free survival (P = .008). Collectively, we demonstrated for the first time a biphasic alteration of BChE, its down-regulation at early stage of PC and its up-regulation at advanced PC.
doi_str_mv 10.1016/j.tranon.2018.06.003
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ce0975da21d74fe09836967cf0c25677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1936523318301888</els_id><doaj_id>oai_doaj_org_article_ce0975da21d74fe09836967cf0c25677</doaj_id><sourcerecordid>2063719440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhlcIREvhHyC0x_aQxZ-z6wtSk7ZQqRIcgKtl7NnE0WYdbG-k_Hsc0pb2gmTJHzPzjud9quo9JQ0lFD6umxzNGMaGEdo1BBpC-IvqlCoOM8k4f_nkfFK9SWlNCFDF2OvqhCkF0IE4rX7O_XZlkrf15ZAxmuzDWIe-nk95H_eDXYXBj5gOoYT1-Xyxur6or6box2X9LYaUTcZ6YUaLsb7CHQ5hu8Exv61e9WZI-O5-P6t-3Fx_X3yZ3X39fLu4vJtZqWSecQq2LGup48Zw6EXfKYPcqB4ACKOdErSjzChwnZMtYcQKJ1UvOqcsZfysuj3qumDWehv9xsS9Dsbrvw8hLrWJ2dsBtUWiWukMo64Vfbl0HBS0tieWSWjbovXpqLWdfm3Q2TJGNMMz0eeR0a_0Muw0EE6ZlEXg_F4ght9TMU1vfLI4DGbEMCXNCPCWKiFISRXHVFs8TBH7xzaU6ANevdZHvPqAVxPQBW8p-_D0i49FDzz_zYDF9J3HqJP1WOg4H9Hm4or_f4c_UBe4uQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2063719440</pqid></control><display><type>article</type><title>Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development</title><source>ScienceDirect Journals</source><source>PubMed Central</source><creator>Gu, Yan ; Chow, Mathilda Jing ; Kapoor, Anil ; Mei, Wenjuan ; Jiang, Yanzhi ; Yan, Judy ; De Melo, Jason ; Seliman, Maryam ; Yang, Huixiang ; Cutz, Jean-Claude ; Bonert, Michael ; Major, Pierre ; Tang, Damu</creator><creatorcontrib>Gu, Yan ; Chow, Mathilda Jing ; Kapoor, Anil ; Mei, Wenjuan ; Jiang, Yanzhi ; Yan, Judy ; De Melo, Jason ; Seliman, Maryam ; Yang, Huixiang ; Cutz, Jean-Claude ; Bonert, Michael ; Major, Pierre ; Tang, Damu</creatorcontrib><description>Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed in PC and its impact on PC remain unclear. We report here the biphasic changes of BChE expression in PC. In vitro, BChE expression was decreased in more tumorigenic PC stem-like cells (PCSLCs), DU145, and PC3 cells compared to less tumorigenic non-stem PCs and LNCaP cells. On the other hand, BChE was expressed at a higher level in LNCaP cells than immortalized but non-tumorigenic prostate epithelial BPH-1 cells. In vivo, BChE expression was up-regulated in DU145 xenografts compared to LNCaP xenografts; DU145 cell-derived lung metastases displayed comparable levels of BChE as subcutaneous tumors. Furthermore, LNCaP xenografts produced in castrated mice exhibited a significant increase of BChE expression compared to xenografts generated in intact mice. In patients, BChE expression was down-regulated in PCs (n = 340) compared to prostate tissues (n = 86). In two independent PC populations MSKCC (n = 130) and TCGA Provisional (n = 490), BChE mRNA levels were reduced from World Health Organization grade group 1 (WHOGG 1) PCs to WHOGG 3 PCs, followed by a significant increase in WHOGG 5 PCs. The up-regulation was associated with a reduction in disease-free survival (P = .008). Collectively, we demonstrated for the first time a biphasic alteration of BChE, its down-regulation at early stage of PC and its up-regulation at advanced PC.</description><identifier>ISSN: 1936-5233</identifier><identifier>EISSN: 1936-5233</identifier><identifier>DOI: 10.1016/j.tranon.2018.06.003</identifier><identifier>PMID: 29966864</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Original article</subject><ispartof>Translational oncology, 2018-08, Vol.11 (4), p.1012-1022</ispartof><rights>2018 The Authors</rights><rights>Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>2018 The Authors 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123</citedby><cites>FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123</cites><orcidid>0000-0001-6519-4879</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031255/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1936523318301888$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29966864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Yan</creatorcontrib><creatorcontrib>Chow, Mathilda Jing</creatorcontrib><creatorcontrib>Kapoor, Anil</creatorcontrib><creatorcontrib>Mei, Wenjuan</creatorcontrib><creatorcontrib>Jiang, Yanzhi</creatorcontrib><creatorcontrib>Yan, Judy</creatorcontrib><creatorcontrib>De Melo, Jason</creatorcontrib><creatorcontrib>Seliman, Maryam</creatorcontrib><creatorcontrib>Yang, Huixiang</creatorcontrib><creatorcontrib>Cutz, Jean-Claude</creatorcontrib><creatorcontrib>Bonert, Michael</creatorcontrib><creatorcontrib>Major, Pierre</creatorcontrib><creatorcontrib>Tang, Damu</creatorcontrib><title>Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development</title><title>Translational oncology</title><addtitle>Transl Oncol</addtitle><description>Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed in PC and its impact on PC remain unclear. We report here the biphasic changes of BChE expression in PC. In vitro, BChE expression was decreased in more tumorigenic PC stem-like cells (PCSLCs), DU145, and PC3 cells compared to less tumorigenic non-stem PCs and LNCaP cells. On the other hand, BChE was expressed at a higher level in LNCaP cells than immortalized but non-tumorigenic prostate epithelial BPH-1 cells. In vivo, BChE expression was up-regulated in DU145 xenografts compared to LNCaP xenografts; DU145 cell-derived lung metastases displayed comparable levels of BChE as subcutaneous tumors. Furthermore, LNCaP xenografts produced in castrated mice exhibited a significant increase of BChE expression compared to xenografts generated in intact mice. In patients, BChE expression was down-regulated in PCs (n = 340) compared to prostate tissues (n = 86). In two independent PC populations MSKCC (n = 130) and TCGA Provisional (n = 490), BChE mRNA levels were reduced from World Health Organization grade group 1 (WHOGG 1) PCs to WHOGG 3 PCs, followed by a significant increase in WHOGG 5 PCs. The up-regulation was associated with a reduction in disease-free survival (P = .008). Collectively, we demonstrated for the first time a biphasic alteration of BChE, its down-regulation at early stage of PC and its up-regulation at advanced PC.</description><subject>Original article</subject><issn>1936-5233</issn><issn>1936-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kU1vEzEQhlcIREvhHyC0x_aQxZ-z6wtSk7ZQqRIcgKtl7NnE0WYdbG-k_Hsc0pb2gmTJHzPzjud9quo9JQ0lFD6umxzNGMaGEdo1BBpC-IvqlCoOM8k4f_nkfFK9SWlNCFDF2OvqhCkF0IE4rX7O_XZlkrf15ZAxmuzDWIe-nk95H_eDXYXBj5gOoYT1-Xyxur6or6box2X9LYaUTcZ6YUaLsb7CHQ5hu8Exv61e9WZI-O5-P6t-3Fx_X3yZ3X39fLu4vJtZqWSecQq2LGup48Zw6EXfKYPcqB4ACKOdErSjzChwnZMtYcQKJ1UvOqcsZfysuj3qumDWehv9xsS9Dsbrvw8hLrWJ2dsBtUWiWukMo64Vfbl0HBS0tieWSWjbovXpqLWdfm3Q2TJGNMMz0eeR0a_0Muw0EE6ZlEXg_F4ght9TMU1vfLI4DGbEMCXNCPCWKiFISRXHVFs8TBH7xzaU6ANevdZHvPqAVxPQBW8p-_D0i49FDzz_zYDF9J3HqJP1WOg4H9Hm4or_f4c_UBe4uQ</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Gu, Yan</creator><creator>Chow, Mathilda Jing</creator><creator>Kapoor, Anil</creator><creator>Mei, Wenjuan</creator><creator>Jiang, Yanzhi</creator><creator>Yan, Judy</creator><creator>De Melo, Jason</creator><creator>Seliman, Maryam</creator><creator>Yang, Huixiang</creator><creator>Cutz, Jean-Claude</creator><creator>Bonert, Michael</creator><creator>Major, Pierre</creator><creator>Tang, Damu</creator><general>Elsevier Inc</general><general>Neoplasia Press</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6519-4879</orcidid></search><sort><creationdate>20180801</creationdate><title>Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development</title><author>Gu, Yan ; Chow, Mathilda Jing ; Kapoor, Anil ; Mei, Wenjuan ; Jiang, Yanzhi ; Yan, Judy ; De Melo, Jason ; Seliman, Maryam ; Yang, Huixiang ; Cutz, Jean-Claude ; Bonert, Michael ; Major, Pierre ; Tang, Damu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Original article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Yan</creatorcontrib><creatorcontrib>Chow, Mathilda Jing</creatorcontrib><creatorcontrib>Kapoor, Anil</creatorcontrib><creatorcontrib>Mei, Wenjuan</creatorcontrib><creatorcontrib>Jiang, Yanzhi</creatorcontrib><creatorcontrib>Yan, Judy</creatorcontrib><creatorcontrib>De Melo, Jason</creatorcontrib><creatorcontrib>Seliman, Maryam</creatorcontrib><creatorcontrib>Yang, Huixiang</creatorcontrib><creatorcontrib>Cutz, Jean-Claude</creatorcontrib><creatorcontrib>Bonert, Michael</creatorcontrib><creatorcontrib>Major, Pierre</creatorcontrib><creatorcontrib>Tang, Damu</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><jtitle>Translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Yan</au><au>Chow, Mathilda Jing</au><au>Kapoor, Anil</au><au>Mei, Wenjuan</au><au>Jiang, Yanzhi</au><au>Yan, Judy</au><au>De Melo, Jason</au><au>Seliman, Maryam</au><au>Yang, Huixiang</au><au>Cutz, Jean-Claude</au><au>Bonert, Michael</au><au>Major, Pierre</au><au>Tang, Damu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development</atitle><jtitle>Translational oncology</jtitle><addtitle>Transl Oncol</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>11</volume><issue>4</issue><spage>1012</spage><epage>1022</epage><pages>1012-1022</pages><issn>1936-5233</issn><eissn>1936-5233</eissn><abstract>Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed in PC and its impact on PC remain unclear. We report here the biphasic changes of BChE expression in PC. In vitro, BChE expression was decreased in more tumorigenic PC stem-like cells (PCSLCs), DU145, and PC3 cells compared to less tumorigenic non-stem PCs and LNCaP cells. On the other hand, BChE was expressed at a higher level in LNCaP cells than immortalized but non-tumorigenic prostate epithelial BPH-1 cells. In vivo, BChE expression was up-regulated in DU145 xenografts compared to LNCaP xenografts; DU145 cell-derived lung metastases displayed comparable levels of BChE as subcutaneous tumors. Furthermore, LNCaP xenografts produced in castrated mice exhibited a significant increase of BChE expression compared to xenografts generated in intact mice. In patients, BChE expression was down-regulated in PCs (n = 340) compared to prostate tissues (n = 86). In two independent PC populations MSKCC (n = 130) and TCGA Provisional (n = 490), BChE mRNA levels were reduced from World Health Organization grade group 1 (WHOGG 1) PCs to WHOGG 3 PCs, followed by a significant increase in WHOGG 5 PCs. The up-regulation was associated with a reduction in disease-free survival (P = .008). Collectively, we demonstrated for the first time a biphasic alteration of BChE, its down-regulation at early stage of PC and its up-regulation at advanced PC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29966864</pmid><doi>10.1016/j.tranon.2018.06.003</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6519-4879</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1936-5233
ispartof Translational oncology, 2018-08, Vol.11 (4), p.1012-1022
issn 1936-5233
1936-5233
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ce0975da21d74fe09836967cf0c25677
source ScienceDirect Journals; PubMed Central
subjects Original article
title Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A58%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biphasic%20Alteration%20of%20Butyrylcholinesterase%20(BChE)%20During%20Prostate%20Cancer%20Development&rft.jtitle=Translational%20oncology&rft.au=Gu,%20Yan&rft.date=2018-08-01&rft.volume=11&rft.issue=4&rft.spage=1012&rft.epage=1022&rft.pages=1012-1022&rft.issn=1936-5233&rft.eissn=1936-5233&rft_id=info:doi/10.1016/j.tranon.2018.06.003&rft_dat=%3Cproquest_doaj_%3E2063719440%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2063719440&rft_id=info:pmid/29966864&rfr_iscdi=true